We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.17B
AUM Growth
+$18.3M
Cap. Flow
-$273M
Cap. Flow %
-4.42%
Top 10 Hldgs %
39.22%
Holding
178
New
12
Increased
57
Reduced
71
Closed
15

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$25.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
3
EXAS
Exact Sciences
EXAS
+$16.4M
4
ABT icon
Abbott
ABT
+$15.1M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$13M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$36.6M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$34.7M
3
CRL icon
Charles River Laboratories
CRL
+$33.2M
4
ARGX icon
argenx
ARGX
+$29.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.04%
3 Communication Services 0.02%
4 Technology 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
101
Gilead Sciences
GILD
$166B
$3.86M 0.06%
46,027
+7,093
+18% +$541K
CAH icon
102
Cardinal Health
CAH
$53.2B
$3.34M 0.05%
30,224
-2,358
-7% -$247K
AZN icon
103
AstraZeneca
AZN
$259B
$2.61M 0.04%
16,750
-4,350
-21% -$702K
RXRX icon
104
Recursion Pharmaceuticals
RXRX
$1.52B
$2.59M 0.04%
392,881
-32,929
-8% -$236K
ACCD
105
DELISTED
Accolade Inc
ACCD
$2.47M 0.04%
640,865
-201,712
-24% -$790K
BMY icon
106
Bristol-Myers Squibb
BMY
$124B
$1.91M 0.03%
+36,825
New +$1.73M
EHC icon
107
Encompass Health
EHC
$11.1B
$1.86M 0.03%
19,233
+5,365
+39% +$482K
MTEM
108
DELISTED
Molecular Templates, Inc.
MTEM
$1.8M 0.03%
1,279,820
– –
RDY icon
109
Dr. Reddy's Laboratories
RDY
$10.5B
$1.64M 0.03%
102,975
-13,665
-12% -$220K
SMMT icon
110
Summit Therapeutics
SMMT
$10.9B
$1.4M 0.02%
+64,094
New +$896K
CVS icon
111
CVS Health
CVS
$138B
$1.39M 0.02%
22,066
– –
PCVX icon
112
Vaxcyte
PCVX
$8.01B
$1.37M 0.02%
11,981
-2,229
-16% -$201K
TEVA icon
113
Teva Pharmaceuticals
TEVA
$36.8B
$1.28M 0.02%
70,821
-83,949
-54% -$1.47M
DOCS icon
114
Doximity
DOCS
$3.84B
$1.27M 0.02%
29,060
-43,095
-60% -$1.44M
CERT icon
115
Certara
CERT
$1.07B
$1.12M 0.02%
95,924
– –
BNTX icon
116
BioNTech
BNTX
$23.4B
$1.04M 0.02%
+8,721
New +$802K
ZTS icon
117
Zoetis
ZTS
$31.7B
$1.03M 0.02%
5,284
+2,343
+80% +$432K
VKTX icon
118
Viking Therapeutics
VKTX
$4.31B
$1.02M 0.02%
16,179
+11,779
+268% +$691K
GOOG icon
119
Alphabet (Google) Class C
GOOG
$4.35T
$1M 0.02%
6,000
– –
THC icon
120
Tenet Healthcare
THC
$16.7B
$935K 0.02%
5,625
+211
+4% +$31.9K
SNY icon
121
Sanofi
SNY
$105B
$871K 0.01%
+15,109
New +$816K
KRYS icon
122
Krystal Biotech
KRYS
$10.3B
$870K 0.01%
4,779
+581
+14% +$112K
RYTM icon
123
Rhythm Pharmaceuticals
RYTM
$7.2B
$823K 0.01%
15,700
+2,700
+21% +$129K
AMRX icon
124
Amneal Pharmaceuticals
AMRX
$5.66B
$636K 0.01%
76,414
+13,654
+22% +$107K
CYTK icon
125
Cytokinetics
CYTK
$10.9B
$578K 0.01%
10,941
-5,718
-34% -$319K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2024 Portfolio in Review

As of Q3 2024, Bellevue Group held 178 positions worth $6.17B, up 0.3% from $6.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group withdrew a net $273M in Q3 2024, closing 15 positions and reducing 71 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Terns Pharmaceuticals worth $8.69M.

  • Bellevue Group's largest Q3 2024 buy was Terns Pharmaceuticals: 1,042,135 shares worth $8.69M.
  • Bellevue Group added most to Evolent Health in Q3 2024, an estimated $25.8M increase.
  • Bellevue Group's biggest Q3 2024 reduction was Insmed, cutting an estimated $36.6M.
  • Bellevue Group fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $23.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $6.17B portfolio in Q3 2024.
  • Bellevue Group opened 12 new positions and closed 15 in Q3 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.17B.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.